Pasteurized Akkermansia muciniphila Ameliorate the LPS-Induced Intestinal Barrier Dysfunction via Modulating AMPK and...

Area of Science:

• Microbiology
• Immunology
• Gastroenterology

Background:

• Akkermansia muciniphila is recognized for reducing inflammation and improving gut barrier function.
• Its beneficial effects are mediated by interactions between its wall components and Toll-like receptor 2 (TLR2) on intestinal cells.
• Understanding the downstream mechanisms of pasteurized A. muciniphila is crucial for its therapeutic applications.

Purpose of the Study:

• To investigate the protective effects of live and pasteurized Akkermansia muciniphila on intestinal epithelial barrier dysfunction.
• To elucidate the specific molecular mechanisms by which A. muciniphila modulates inflammatory and barrier pathways.
• To confirm the role of Toll-like receptor 2 (TLR2) in mediating these effects.

Main Methods:

• Utilized Caco-2 intestinal epithelial cell monolayers to model barrier dysfunction induced by lipopolysaccharide (LPS).
• Assessed the impact of both live and pasteurized A. muciniphila on inflammatory markers and barrier integrity.
• Investigated the activation status of key signaling pathways, including AMP-activated protein kinase (AMPK) and Nuclear Factor-Kappa B (NF-κB), via TLR2 stimulation.

Main Results:

• Both live and pasteurized A. muciniphila significantly attenuated inflammatory responses in Caco-2 cells.
• Treatment with A. muciniphila improved the integrity of the intestinal epithelial barrier.
• A. muciniphila was shown to enhance AMPK activation and inhibit NF-κB activation, mediated through TLR2 stimulation.

Conclusions:

• Akkermansia muciniphila, in both live and pasteurized forms, effectively restores intestinal barrier function.
• The probiotic exerts its beneficial effects by activating TLR2, leading to enhanced AMPK and suppressed NF-κB signaling.
• These findings provide a mechanistic basis for the use of A. muciniphila as a therapeutic agent for gut health.